These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 994150)

  • 1. Catechol O-methyltransferase. 9. Mechanism of inactivation by 6-hydroxydopamine.
    Borchardt RT; Reid JR; Thakker DR
    J Med Chem; 1976 Oct; 19(10):1201-9. PubMed ID: 994150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catechol O-methyltransferase. 12. Affinity labeling the active site with the oxidation products of 5,6-dihydroxyindole.
    Borchardt RT; Bhatia P
    J Med Chem; 1982 Mar; 25(3):263-71. PubMed ID: 7069705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
    Borchardt RT; Smissman EE; Nerland D; Reid JR
    J Med Chem; 1976 Jan; 19(1):30-7. PubMed ID: 1246049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that 6-hydroxydopamine is an inhibitor of catechol-O-methyltransferase in intact tissue.
    Reid JJ; Stitzel RE; Head RJ
    J Pharm Pharmacol; 1986 Jan; 38(1):46-50. PubMed ID: 2869126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites.
    Liang SC; Ge GB; Xia YL; Pei-Pei D; Ping W; Qi XY; Cai-Xia T; Ling Y
    Xenobiotica; 2017 Jun; 47(6):498-504. PubMed ID: 27435571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.
    Palma PN; Bonifácio MJ; Loureiro AI; Wright LC; Learmonth DA; Soares-da-Silva P
    Drug Metab Dispos; 2003 Mar; 31(3):250-8. PubMed ID: 12584150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equine catechol estrogen 4-hydroxyequilenin is a more potent inhibitor of the variant form of catechol-O-methyltransferase.
    Li Y; Yao J; Chang M; Nikolic D; Yu L; Yager JD; Mesecar AD; van Breemen RB; Bolton JL
    Chem Res Toxicol; 2004 Apr; 17(4):512-20. PubMed ID: 15089093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of catechol-O-methyltransferase by 1-vinyl derivatives of nitrocatechols and nitroguaiacols. Kinetics of the irreversible inhibition by 3-(3-hydroxy-4-methoxy-5-nitro benzylidene)-2,4-pentanedione.
    Pérez RA; Fernández-Alvarez E; Nieto O; Piedrafita FJ
    Biochem Pharmacol; 1993 May; 45(10):1973-81. PubMed ID: 8512582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol estrogen 4-hydroxyequilenin is a substrate and an inhibitor of catechol-O-methyltransferase.
    Yao J; Li Y; Chang M; Wu H; Yang X; Goodman JE; Liu X; Liu H; Mesecar AD; Van Breemen RB; Yager JD; Bolton JL
    Chem Res Toxicol; 2003 May; 16(5):668-75. PubMed ID: 12755597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of catechol-O-methyltransferase by 6,7-dihydroxy-3,4-dihydroisoquinolines related to dopamine: demonstration using liquid chromatography and a novel substrate for O-methylation.
    Cheng BY; Origitano TC; Collins MA
    J Neurochem; 1987 Mar; 48(3):779-86. PubMed ID: 2433397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
    Lautala P; Ulmanen I; Taskinen J
    Mol Pharmacol; 2001 Feb; 59(2):393-402. PubMed ID: 11160877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-electron oxidation of C(2) and C(3) methyl substituted 5,6-dihydroxyindoles: model pathways of melanogenesis.
    al-Kazwini AT; O'Neill P; Adams GE; Cundall RB; Maignan J; Junino A
    Melanoma Res; 1994 Dec; 4(6):343-50. PubMed ID: 7703713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.
    Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS
    Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation.
    Meyer MR; Maurer HH
    Chem Res Toxicol; 2009 Jun; 22(6):1205-11. PubMed ID: 19462939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate.
    Lu H; Meng X; Yang CS
    Drug Metab Dispos; 2003 May; 31(5):572-9. PubMed ID: 12695345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation.
    Palma PN; Rodrigues ML; Archer M; Bonifácio MJ; Loureiro AI; Learmonth DA; Carrondo MA; Soares-da-Silva P
    Mol Pharmacol; 2006 Jul; 70(1):143-53. PubMed ID: 16618795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 2-and/or 5-methylated analogues of 6-hydroxydopamine on norepinephrine-and dopamine-containing neurons.
    Liang YO; Adams RN
    Mol Pharmacol; 1977 Sep; 13(5):805-18. PubMed ID: 895717
    [No Abstract]   [Full Text] [Related]  

  • 18. Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 10. Base- and amino acid modified analogues of S-aristeromycinyl-L-homocysteine.
    Houston DM; Matuszewska B; Borchardt RT
    J Med Chem; 1985 Apr; 28(4):478-82. PubMed ID: 3981540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular orbital studies on the structure-activity relationships of catechol O-methyltransferase inhibitors.
    Shinagawa Y
    Jpn J Pharmacol; 1992 Feb; 58(2):95-106. PubMed ID: 1507526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies.
    Chen D; Wang CY; Lambert JD; Ai N; Welsh WJ; Yang CS
    Biochem Pharmacol; 2005 May; 69(10):1523-31. PubMed ID: 15857617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.